1. Home
  2. OBIO vs VNDA Comparison

OBIO vs VNDA Comparison

Compare OBIO & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • VNDA
  • Stock Information
  • Founded
  • OBIO 2017
  • VNDA N/A
  • Country
  • OBIO United States
  • VNDA United States
  • Employees
  • OBIO N/A
  • VNDA N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • VNDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • OBIO Health Care
  • VNDA Health Care
  • Exchange
  • OBIO Nasdaq
  • VNDA Nasdaq
  • Market Cap
  • OBIO 291.7M
  • VNDA 362.6M
  • IPO Year
  • OBIO N/A
  • VNDA 2006
  • Fundamental
  • Price
  • OBIO $8.03
  • VNDA $6.07
  • Analyst Decision
  • OBIO Strong Buy
  • VNDA Buy
  • Analyst Count
  • OBIO 2
  • VNDA 1
  • Target Price
  • OBIO $17.00
  • VNDA $11.00
  • AVG Volume (30 Days)
  • OBIO 247.1K
  • VNDA 955.3K
  • Earning Date
  • OBIO 08-08-2024
  • VNDA 07-29-2024
  • Dividend Yield
  • OBIO N/A
  • VNDA N/A
  • EPS Growth
  • OBIO N/A
  • VNDA N/A
  • EPS
  • OBIO N/A
  • VNDA N/A
  • Revenue
  • OBIO $2,216,000.00
  • VNDA $177,604,000.00
  • Revenue This Year
  • OBIO $17.90
  • VNDA $2.98
  • Revenue Next Year
  • OBIO $10.51
  • VNDA $19.49
  • P/E Ratio
  • OBIO N/A
  • VNDA N/A
  • Revenue Growth
  • OBIO N/A
  • VNDA N/A
  • 52 Week Low
  • OBIO $4.22
  • VNDA $3.30
  • 52 Week High
  • OBIO $11.69
  • VNDA $6.75
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 54.76
  • VNDA 57.74
  • Support Level
  • OBIO $7.48
  • VNDA $5.75
  • Resistance Level
  • OBIO $8.75
  • VNDA $5.39
  • Average True Range (ATR)
  • OBIO 0.60
  • VNDA 0.27
  • MACD
  • OBIO 0.01
  • VNDA 0.05
  • Stochastic Oscillator
  • OBIO 59.03
  • VNDA 78.99

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.

Share on Social Networks: